Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1

Interventions

Paclitaxel 58Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 38Bevacizumab 37pembrolizumab 33Nivolumab 30Cisplatin 28Fluorouracil 24Irinotecan 23Capecitabine 23Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16regorafenib 15Ipilimumab 15Blood Specimen Collection 14Albumin-Bound Paclitaxel 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × ASTX029 × Tumor-Agnostic × Clear all
NCT03520075 2025-07-03

Study of ASTX029 in Subjects With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1/2 Completed
192 enrolled 56 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡